0001193125-20-297203.txt : 20201119 0001193125-20-297203.hdr.sgml : 20201119 20201118191902 ACCESSION NUMBER: 0001193125-20-297203 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201119 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201119 DATE AS OF CHANGE: 20201118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Syneos Health, Inc. CENTRAL INDEX KEY: 0001610950 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 273403111 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36730 FILM NUMBER: 201326611 BUSINESS ADDRESS: STREET 1: 1030 SYNC STREET CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-876-9300 MAIL ADDRESS: STREET 1: 1030 SYNC STREET CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: INC Research Holdings, Inc. DATE OF NAME CHANGE: 20140616 8-K 1 d36851d8k.htm 8-K 8-K
false 0001610950 0001610950 2020-11-19 2020-11-19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 19, 2020

 

 

SYNEOS HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36730   27-3403111
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

1030 Sync Street

Morrisville, North Carolina

   27560-5468
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (919) 876-9300

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Class A Common Stock,
$0.01 par value per share		   SYNH   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01.

Other Events.

On November 18, 2020, Syneos Health, Inc. (the “Company”) announced the upsizing and pricing of an offering of $600.0 million aggregate principal amount of 3.625% Senior Notes due 2029 (the “Notes”), an upsize of $100.0 million over the amount previously announced. The Notes were priced at par value and will bear an interest rate of 3.625% per annum. The Notes are being offered in a private offering to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A and to certain persons outside the United States under Regulation S of the Securities Act of 1933, as amended. The Company also announced that it intends to enter into an amendment to the credit agreement governing its existing senior secured credit facilities pursuant to which, among other things, the Issuer expects to extend the maturity date thereof to August 2024 (the “Amendment”). The closing of the offering is not conditioned upon the effectiveness of the Amendment.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.		    Description
99.1    Press Release issued on November 18, 2020
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      SYNEOS HEALTH, INC.
Date: November 19, 2020     By:  

/s/ Jason Meggs

    Name:   Jason Meggs
    Title:   Chief Financial Officer (Principal Financial Officer)
 EX-99.1 2 d36851dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

FOR IMMEDIATE RELEASE

Syneos Health Announces Upsizing and Pricing of Offering of $600.0 Million of Senior Notes due 2029

MORRISVILLE, N.C. – November 18, 2020 — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced the upsizing and pricing of an offering of $600.0 million aggregate principal amount of 3.625% senior notes due 2029 (the “Notes”), an upsize of $100.0 million over the amount previously announced. The Notes were priced at par value and will bear an interest rate of 3.625% per annum. The Notes are being offered in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be guaranteed, jointly and severally, on a senior unsecured basis, by certain of the Company’s subsidiaries. Syneos Health expects to close the offering of the Notes on November 24, 2020, subject to the satisfaction of customary closing conditions.

Syneos Health intends to use the net proceeds of this offering for general corporate purposes, including the funding of acquisitions, and for repayment of indebtedness.

The Company also announced that it intends to enter into an amendment to the credit agreement governing its existing senior secured credit facilities pursuant to which, among other things, the Company expects to extend the maturity date thereof to August 2024 (the “Amendment”). The closing of the offering is not conditioned upon the effectiveness of the Amendment.

The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act, and outside the United States, only to non-U.S. investors pursuant to Regulation S. The Notes will not be and have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers of the Notes will be made only by means of a private offering memorandum.

Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: reliance on key personnel; principal investigators and patients; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; any inability to satisfy or any failure to waive the closing conditions related to our

 

1

acquisition of SHCR Holdings Corporation (“Synteract”); any failure to realize the anticipated benefits of the acquisition of Synteract; risks related to the COVID-19 pandemic; the Company’s ability to adequately price its contracts and not overrun cost estimates; any adverse effects from the Company’s customer or therapeutic area concentration; the Company’s ability to maintain or generate new business awards; the Company’s ability to increase its market share, grow its business, and execute its growth strategies; the Company’s backlog not being indicative of future revenues and its ability to realize the anticipated future revenue reflected in its backlog; fluctuations in the Company’s operating results and effective income tax rate; risks related to the Company’s information systems and cybersecurity; changes and costs of compliance with regulations related to data privacy; risks related to the United Kingdom’s withdrawal from the European Union; risks related to the Company’s transfer pricing policies; failure to perform services in accordance with contractual requirements, regulatory requirements and ethical considerations; risks relating to litigation and government investigations; risks associated with the Company’s early phase clinical facilities; insurance risk; risks of liability resulting from harm to patients; success of investments in the Company’s customers’ business or drugs; foreign currency exchange rate fluctuations; risks associated with acquired businesses, including the ability to integrate acquired operations, products, and technologies in our business; risks related to the Company’s income tax expense and tax reform; risks relating to the Company’s intellectual property; risks associated with the Company’s acquisition strategy; failure to realize the full value of goodwill and intangible assets; restructuring risk; potential violations of anti-corruption and anti-bribery laws; risks related to the Company’s dependence on third parties; downgrades of the Company’s credit ratings; competition in the biopharmaceutical services industry; changes in outsourcing trends; regulatory risks; trends in the Company’s customers’ businesses; the Company’s ability to keep pace with rapid technological change; risks related to the Company’s indebtedness; fluctuations in the Company’s financial results and stock price; and other risk factors set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as updated by the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and other SEC filings, copies of which are available free of charge on the SEC website at www.sec.gov. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

About Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

 

Investor Relations Contact:

 

Ronnie Speight

Senior Vice President, Investor Relations

Phone: +1 919 745 2745

Email: Investor.Relations@syneoshealth.com

   

Press/Media Contact:

 

Danielle DeForge

Executive Director, External Communications

Phone: +1 202 210 5992

Email: danielle.deforge@syneoshealth.com

 

2

EX-101.SCH 3 synh-20201119.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 synh-20201119_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 synh-20201119_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g36851g1118111303604.jpg GRAPHIC begin 644 g36851g1118111303604.jpg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end XML 7 d36851d8k_htm.xml IDEA: XBRL DOCUMENT 0001610950 2020-11-19 2020-11-19 false 0001610950 8-K 2020-11-19 SYNEOS HEALTH, INC. DE 001-36730 27-3403111 1030 Sync Street Morrisville NC 27560-5468 (919) 876-9300 false false false false Class A Common Stock,$0.01 par value per share SYNH NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Nov. 19, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001610950
Document Type 8-K
Document Period End Date Nov. 19, 2020
Entity Registrant Name SYNEOS HEALTH, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-36730
Entity Tax Identification Number 27-3403111
Entity Address, Address Line One 1030 Sync Street
Entity Address, City or Town Morrisville
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27560-5468
City Area Code (919)
Local Phone Number 876-9300
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Class A Common Stock,$0.01 par value per share
Trading Symbol SYNH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d36851d8k.htm d36851dex991.htm synh-20201119.xsd synh-20201119_lab.xml synh-20201119_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d36851d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d36851d8k.htm" ] }, "labelLink": { "local": [ "synh-20201119_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "synh-20201119_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "synh-20201119.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "synh", "nsuri": "http://www.syneoshealth.com/20201119", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d36851d8k.htm", "contextRef": "duration_2020-11-19_to_2020-11-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d36851d8k.htm", "contextRef": "duration_2020-11-19_to_2020-11-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.syneoshealth.com//20201119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-20-297203-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-297203-xbrl.zip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end